ExSURE PVT. LTD.

• 22/01/2025
• Seed
• $347,401

EXSURE is an R & D-based startup and we are developing the next generation of exosome-based cancer therapeutics. We are developing a unique exosome-based chemotherapeutic drug-delivery platform that will facilitate precise and guided delivery of anti-cancer drugs (existing on the market) into tumor cells and relapse-causing cells (cancer stem cells) without abruptly harming the healthy cells. Our platform will reduce chemotoxicity and chances of cancer relapse in cancer patients. Currently, we are working with a breast cancer model. We have validated the efficiency and efficacy of our platform in vitro (in different breast cancer cell lines and derived cancer stem cells) and ex-vivo (primary cells & stem cells derived from chemo-naive clinical samples of breast tumor biopsies). We are yet to validate our platform in vivo (SCID mice). We have filed the patent for the formulation we are using to develop these bioengineered drug-loaded targeted exosomes and the methodology behind it (Final patent to be filed this month). We are providing outsourcing services including any type of cell-culture-based assays, exosome-based experimentations, and cancer stem cell-based assays.

---

---